Clinical Scorecard: Complete Remission of Catatonia and Psychotic Symptoms in a Parkinson's Disease Patient with Acromegaly Following Lorazepam Treatment: A Case Study
At a Glance
Category
Detail
Condition
Parkinson's Disease with Catatonia and Psychosis
Key Mechanisms
Dopamine deficiency and cortical dysregulation
Target Population
Patients with Parkinson's Disease and comorbid acromegaly
Care Setting
Tertiary hospital, Emergency Department
Key Highlights
Lorazepam treatment led to complete resolution of catatonia and psychosis.
Patient had a history of Parkinson's Disease and major depressive disorder.
Acromegaly was confirmed via MRI and hormonal studies.
Symptoms worsened after abrupt medication discontinuation.
Significant improvement observed within six days of treatment.
Guideline-Based Recommendations
Diagnosis
Assess for catatonia and psychosis in Parkinson's Disease patients, especially after medication changes.
Management
Consider lorazepam for treatment of catatonia and psychosis in PD patients.
Monitoring & Follow-up
Regularly monitor neuropsychiatric symptoms and medication adherence.
Risks
Be aware of potential exacerbation of symptoms following medication withdrawal.
Patient & Prescribing Data
Older adults with Parkinson's Disease and comorbid psychiatric conditions.
Lorazepam can be effective in managing complex neuropsychiatric symptoms.
Clinical Best Practices
Recognize the interplay between Parkinson's Disease and psychiatric symptoms.
Implement a multidisciplinary approach involving neurology, psychiatry, and endocrinology.
